BioNTech, Pfizer sue CureVac in US over COVID-19 vaccine patent claims, Health News, ET HealthWorld


BioNTech, Pfizer sue CureVac in US over COVID-19 vaccine patent claims

Frankfurt: COVID-19 vaccine maker BioNTech stated on Tuesday that it and accomplice Pfizer have filed a criticism with the US District Court in Massachusetts, in search of a judgment that they didn’t infringe US patents held by rival CureVac,

The lawsuit, filed Monday, stated CureVac is making an attempt to revenue from the success of BioNTech and Pfizer’s COVID-19 vaccines after CureVac’s efforts to create its personal vaccine failed.

CureVac filed a patent lawsuit in Germany in opposition to BioNTech over its use of mRNA know-how and didn’t rule out additional authorized motion in opposition to BioNTech’s accomplice Pfizer or rival mRNA vaccine maker moderna Inc.

BioNTech stated that CureVac’s US patents had been equal to German patents invoked by CureVac within the German courtroom case.

BioNTech and Pfizer requested the Boston courtroom to declare that their Comirnaty vaccine doesn’t violate three CureVac patents associated to RNA-based vaccines. The firms informed the courtroom that Comirnaty doesn’t work in the identical means as CureVac’s patented know-how.

One of the patents considerations messenger RNA (mRNA) related to lipid nanoparticles (LNPs), which the vaccines use to ship the molecules safely into the physique. Pfizer, BioNTech, and Moderna have been hit with US patent lawsuits by different biotech firms this 12 months over the LNP know-how used of their vaccines.

Pfizer has stated that it expects $32 billion in income from Comirnaty this 12 months.

CureVac stated in an announcement it was conscious of BioNTech’s authorized motion however had not but been formally served.

“We will review the matter legally in detail and represent our position accordingly,” it added.





Source hyperlink

Leave a Reply

Your email address will not be published.